These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15853560)

  • 1. Paroxetine in panic disorder: clinical management and long-term follow-up.
    Dannon PN; Lowengrub K; Iancu I; Kotler M
    Expert Rev Neurother; 2004 Mar; 4(2):191-8. PubMed ID: 15853560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of panic disorder: focus on paroxetine.
    Pollack MH; Doyle AC
    Psychopharmacol Bull; 2003; 37 Suppl 1():53-63. PubMed ID: 14566201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term treatment of panic disorder.
    Davidson JR
    J Clin Psychiatry; 1998; 59 Suppl 8():17-21; discussion 22-3. PubMed ID: 9707158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbid cannabis use and panic disorder: short term and long term follow-up study.
    Dannon PN; Lowengrub K; Amiaz R; Grunhaus L; Kotler M
    Hum Psychopharmacol; 2004 Mar; 19(2):97-101. PubMed ID: 14994319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacotherapy of panic disorder].
    Bougerol T; Farisse J
    Encephale; 1996 Dec; 22 Spec No 5():46-53. PubMed ID: 9138947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine: a review of clinical experience.
    Dunner D; Kumar R
    Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical effect and tolerance of paxil (paroxetine) in management of panic disorders].
    Mosolov SN; Smulevich AB; Nuller IuL; Grigor'evskikh VS; Kostiukova EG; Kuzavkova MV; Koliutskaia EV; Andriushchenko AV; Zelenina EV; Kosinskiĭ VP; Kozlovskiĭ VL; Bykov SI; Pererva IG
    Ter Arkh; 2000; 72(10):16-23. PubMed ID: 11220870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressants in panic disorder.
    Wade AG
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S13-7. PubMed ID: 10471168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three year naturalistic outcome study of panic disorder patients treated with paroxetine.
    Dannon PN; Iancu I; Cohen A; Lowengrub K; Grunhaus L; Kotler M
    BMC Psychiatry; 2004 Jun; 4():16. PubMed ID: 15191617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy studies of paroxetine in panic disorder.
    Lydiard RB; Steiner M; Burnham D; Gergel I
    Psychopharmacol Bull; 1998; 34(2):175-82. PubMed ID: 9640997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personality disorders and response to medication treatment in panic disorder: a 1-year naturalistic study.
    Marchesi C; De Panfilis C; Cantoni A; Fontò S; Giannelli MR; Maggini C
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1240-5. PubMed ID: 16678956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nocturnal sleep panic and depression: relationship to subjective sleep in panic disorder.
    Singareddy R; Uhde TW
    J Affect Disord; 2009 Jan; 112(1-3):262-6. PubMed ID: 18558437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram in the treatment of generalized anxiety disorder.
    Baldwin DS; Nair RV
    Expert Rev Neurother; 2005 Jul; 5(4):443-9. PubMed ID: 16026227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls.
    Faludi G; Tekes K; Tóthfalusi L
    J Psychiatry Neurosci; 1994 Mar; 19(2):109-13. PubMed ID: 8204562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants?
    Dusseldorp E; Spinhoven P; Bakker A; van Dyck R; van Balkom AJ
    Psychother Psychosom; 2007; 76(3):154-61. PubMed ID: 17426414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying and treating panic disorder in primary care.
    Culpepper L
    J Clin Psychiatry; 2004; 65 Suppl 5():19-23. PubMed ID: 15078114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena.
    Bhanji NH; Chouinard G; Kolivakis T; Margolese HC
    Can J Clin Pharmacol; 2006; 13(1):e69-74. PubMed ID: 16456219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panic disorder and suicidality: is comorbidity with depression the key?
    Diaconu G; Turecki G
    J Affect Disord; 2007 Dec; 104(1-3):203-9. PubMed ID: 17442399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.